LJUIF (SSY Group) ROCE %: 4.99% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LJUIF SSY Group Ltd LJUIF
86 GF Score
Price $0.40
GF Value $0.51
! 8 Warning Signs
View Full Analysis

What is SSY Group ROCE %?

SSY Group LJUIF 86 ROCE % is 4.99% as of Dec. 2025. GuruFocus rates LJUIF with a GF Score™ of 86/100 and a GF Value™ of $0.51. The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SSY Group's annualized ROCE % for the quarter that ended in Dec. 2025 was 4.99%.

SSY Group  (OTCPK:LJUIF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SSY Group ROCE % Related Terms

SSY Group ROCE % Historical Data

* Premium members only.

The historical data trend for SSY Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SSY Group ROCE % Chart

SSY Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.03 17.93 19.25 13.96 6.38

SSY Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.45 17.75 9.81 7.33 4.99
LJUIF
86GF Score
SSY Group Ltd LJUIF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SSY Group ROCE % Calculation

SSY Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=86.023/( ( (1621.386 - 234.254) + (1646.76 - 336.542) )/ 2 )
=86.023/( (1387.132+1310.218)/ 2 )
=86.023/1348.675
=6.38 %

SSY Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=68.214/( ( (1629.876 - 207.375) + (1646.76 - 336.542) )/ 2 )
=68.214/( ( 1422.501 + 1310.218 )/ 2 )
=68.214/1366.3595
=4.99 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 4.99% mean?
SSY Group (LJUIF) has a ROCE % of 4.99% as of Dec. 2025.
Is SSY Group's ROCE % too high?
SSY Group's current ROCE % is 4.99%. The Drug Manufacturers industry median ROCE % is 7.06. SSY Group's value of 4.99% is 29.3% below this industry median. Overall, SSY Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's ROCE % compare to ZTS?
SSY Group's ROCE % of 4.99% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.06. SSY Group's value of 4.99% is 29.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.06, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current ROCE % of 4.99% is 29.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current ROCE % is 4.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current ROCE % of 4.99%. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.1% below its estimated fair value. The current ROCE % is 4.99% and 29.3% below the Drug Manufacturers industry median of 7.06. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For SSY Group (LJUIF), the current ROCE % is 4.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SSY Group (LJUIF) Overvalued in 2026?

Based on GuruFocus' analysis, SSY Group stock appears to be undervalued. The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.

Key valuation signals for LJUIF:

  • ROCE %: 4.99%
  • GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
  • GF Score™: 86/100 with 8 warning signs
  • Industry Position: 29.3% below the Drug Manufacturers median

No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SSY Group Business Description

Other Exchanges 02005:Hong Kong
Address Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score

Get the complete analysis for LJUIF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.51
GF Value